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The HLA-E homolog in the mouse (Qa-1b) is a conserved MHC class Ib molecule 
presenting monomorphic peptides to germline-encoded natural killer receptor CD94/
NKG2A. Previously, we demonstrated the replacement of this canonical peptide by 
a diverse peptidome upon deficiency of the TAP peptide transporter. Analysis of this 
Qa-1b-restricted T cell repertoire against these non-mutated neoantigens revealed char-
acteristics of conventional hypervariable CD8+ T cells, but also of invariant T cell receptor 
(TCR)αβ T cells. A shared TCR Vα chain was used by this subset in combination with 
a variety of Vβ chains. The TCRs target peptide ligands that are conserved between 
mouse and man, like the identified peptide derived from the transcriptional cofactor 
Med15. The thymus selection was studied in a TCR-transgenic mouse and emerging 
naïve CD8+ T  cells displayed a slightly activated phenotype, as witnessed by higher 
CD122 and Ly6C expression. Moreover, the Qa-1b protein was dispensable for thymus 
selection. Importantly, no self-reactivity was observed as reported for other MHC class 
Ib-restricted subsets. Naïve Qa-1b restricted T cells expanded, contracted, and formed 
memory cells in vivo upon peptide vaccination in a similar manner as conventional CD8+ 
T cells. Based on these data, the Qa-1b restricted T cell subset might be positioned 
closest to conventional CD8+ T cells of all MHC class Ib populations.
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inTrODUcTiOn
The non-classical mouse MHC class I (MHC-I) molecule Qa-1b and its human homolog HLA-E are 
non-polymorphic MHC molecules with important functions in innate immunity. These proteins 
bind and present signal peptides of classical MHC-I molecules at the cell surface and, as such, act 
as indirect sensors for the normal expression of MHC-I molecules (1, 2). This signal peptide domi-
nantly accommodated in the groove of Qa-1b is called Qdm, for Qa-1 determinant modifier (3, 4), 
and its amino acid sequence AMAPRTLLL is amazingly conserved among mammalian species (5). 
The Qdm/Qa-1b complex serves as a ligand for the germ-line encoded heterodimeric CD94/NKG2A 
receptors expressed on NK cells and activated CD8+ T cells and transduces inhibitory signals to these 
lymphocytes (5–7). This innate role of Qa-1b and HLA-E has been well characterized.
Although the self-peptide Qdm is the dominant monomorphic peptide presented by Qa-1b and 
HLA-E, other microbial peptides are capable of stabilizing Qa-1b and HLA-E. Examples of these are 
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a heat shock protein 60 derived peptide (8), insulin peptides (9, 
10), and a peptide from the Salmonella enterica bacterium (11). 
Such examples have also been described for the human HLA-E 
homolog, where peptides were found from an endogenous mul-
tidrug resistance transporter protein (12) and from the pathogens 
Cytomegalovirus, Hepatitisvirus, S. enterica bacterium, and 
Mycobacterium tuberculosis (13–17). For some of these alternate 
peptides, specific CD8+ T  cells have been identified, showing 
that Qa-1b and HLA-E are also involved in adaptive immunity 
to present antigens (11, 14, 16, 18–20). Of note, an interesting 
population of Qa-1b regulatory CD8+ T cells have been described 
targeting self-peptides and dampening auto-immunity (21–23). 
The engagement by T cell receptor (TCR) is not surprising as both 
molecules fold like conventional MHC-I molecules and support 
interaction with CD8 (7, 24, 25).
Previously, we and others have reported on the presentation 
of endogenous peptides by Qa-1b on cells with a defect in the 
antigen-processing machinery (26, 27). Defects in the antigen-
processing machinery, as reported for the peptide transporter 
TAP, the peptide-editor tapasin, or the ER-resident amino pepti-
dase ERAAP, results in failure to present Qdm and, consequently, 
allows the display of alternative peptides from endogenous 
sources. Viruses and tumor cells regularly downregulate these 
processing components and thereby evade immune surveil-
lance by CD8+ T  cells. Mass spectrometry analysis of peptides 
from TAP-deficient tumor cells revealed a large and diverse 
repertoire of alternative peptides (27). A similar diversity was 
found for HLA-E (28). Cells deficient for the aminopeptidase 
ERAAP presented the novel peptide FL9 in the context of Qa-1b 
(26). These alternative peptides were immunogenic in that they 
induced CD8+ T cell responses, although the donor proteins were 
of self-origin.
Here, we studied common characteristics of Qa-1b-restricted 
T cells that recognize these alternative peptides on TAP-deficient 
target cells. We demonstrate that these T  lymphocytes display 
features of semi-invariant T cells: 1. a conserved TCR Vα seg-
ment is used, whereas their CDR3 and the TCRβ chains were 
diverse; 2. the Qa-1b presented peptide ligands were shared by 
mouse, human, and monkey cells; 3. the generation in the thymus 
was inefficient in a TCR-transgenic mouse, and 4. the thymus 
education was independent of Qa-1b. Importantly, the emerging 
T  cell repertoire in the periphery still exhibited strong clonal 
expansion and effector functions after peptide vaccination. We 
furthermore show that Qdm-reactive T cells are strictly deleted 
from the repertoire. Based on our results, Qa-1b-restricted CD8+ 
T cells need to be positioned between conventional hypervariable 
TCRαβ T cells and real invariant T cells like NKT and MAIT cells.
MaTerials anD MeThODs
cell lines and Mice
The human tumor cell lines HeLa and T2 and the monkey 
COS-7 cells were derived from ATCC. Gene transfer of H-2T23 
(Qa-1b) and the TAP-inhibitor UL49.5 (BTIP) was performed 
by retroviral transduction as previously described, as well as the 
generation and culture of T cell clones (27). Dendritic cells were 
derived from bone marrow by culture for 1 week in the presence 
of IL-4 and GM-CSF (29). All cells were cultured in complete 
IMDM medium (Invitrogen, Carlsbad, CA, USA) containing 
8% heat-inactivated FCS (Gibco), 100 U/ml penicillin, 100 µg/
ml streptomycin and 2 mM l-glutamine (Invitrogen) at 37°C in 
humidified air with 5% CO2.
C57BL/6 mice were purchased from Charles River (L’Arbresle, 
France). The TAP1−/− mice (The Jackson Laboratory stock no. 
002944), Rag1−/− mice (The Jackson Laboratory stock no. 003729) 
and the Qa-1b−/− mice (The Jackson Laboratory stock no. 007907) 
were bred in our own facility. Rag1−/− mice were a kind gift from 
Dr. Frank Staal (LUMC, Leiden) and Qa-1b−/− mice were kindly 
provided by Marc Vocanson (Lyon, France). Mice were housed 
in individually ventilated cages and used at 6–12 weeks of age. 
All animal experiments were controlled by the animal welfare 
committee (IvD) of the Leiden University Medical Center and 
approved by the national central committee of animal experi-
ments (CCD) under the permit number AVD116002015271.
generation of Tcr-Transgenic ln12 Mouse
The Ln12 TCR-transgenic mouse strain was generated by 
transgenesis of the TCRα and TCRβ genes of the Ln12 T  cell 
clone. The TCRα and TCRβ chains were separately cloned into 
pCRII-TOPO plasmid vectors (Invitrogen) using RT-PCR and 
sequenced. Expression of TCRs was performed by retroviral 
transduction of the TCR genes in C57BL/6 splenocytes using 
pMX vectors (Ton Schumacher, NKI, Amsterdam). For transgen-
esis, the two chains were separately cloned into VA-hCD2 vectors 
(30) and inserts were subsequently injected in C57BL/6 oocytes. 
DNA from tails of founder mice was analyzed by PCR for pres-
ence of the constructs, using the forward primer in the CD2 
cassette 5′-GGT GTG GAC TCC ACC AGT CTC ACT TC-3′ 
and the reverse primer in the TCRα 5′-TAA CTG GTA CAC 
AGC AGG-3′ or TCRβ region 5′-CAA ACA AGG AGA GAC 
CTT G-3′ (Invitrogen). One transgenic founder strain (no 30) 
was selected for further breeding, since this mouse displayed 
highest TCR-Vβ10 protein expression on T cells as determined by 
specific antibody (clone B21.5, Biolegend). All experiments were 
performed with ln12 transgenic mice backcrossed to Rag1−/− 
mice and, for some experiments, subsequently to Qa-1b−/− mice.
Peptide Vaccination, In Vivo cytotoxicity 
assay, and adoptive T cell Transfer
Peptide vaccination was performed at day 1 and day 8 after T cell 
transfer with 50 µg of the Med15 or Qdm peptide together with 
the imiquimod-containing cream Aldara, as described before 
(31). For the in  vivo cytotoxicity assay, immunized mice were 
challenged with three differentially CFSE-labeled populations of 
splenocytes, unloaded or loaded with the Med15 or Qdm peptide, 
as described before (31). Two days after transfer of target cells, 
mice were sacrificed and spleens were analyzed for the presence 
of target cells. For T cell transfer assays, single cell suspensions 
were made by mechanical disruption of spleen and lymph nodes 
from ln12-transgenic mice. Cells were passed through nylon 
wool to enrich for T cells and 1 × 106 CD8+ T cells were injected 
in 200 µl PBS intravenously in recipient mice.
FigUre 1 | T cell receptor (TCR) usage of Qa-1b-restricted T cell clones. Three independent Qa-1b-restricted T cell clones were isolated (Ln12, Ln25, and Ln14). (a) 
TCRβ usage was determined by flow cytometry. Representative data from three independent experiments with similar results. (B) Amino acid sequence and CDR3 
region of the TCRα and TCRβ chains, according to IMGT nomenclature. Complete amino acid sequences are displayed in Figure S1 in Supplementary Material.
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Flow cytometry analysis
For flow cytometry analysis, single cell suspensions were stained 
in 0.1% BSA/PBS with antibodies against CD4 (clone RM4-5), 
CD8 (53.6-7), CD3 (145-2C11), TCRβ (H57-597), Vβ10 (B21.5), 
CD25 (PC61), CD62L (MEL-14), CD122 (TM-b1), Ly6C 
(HK1.4), CD5 (53-7,3), and CD44 (IM7) which were purchased 
from eBioSciences, Biolegend, or Becton and Dickinson (BD). 
For Qa-1b staining, cells were first incubated with Qa-1b-biotin 
(6A8.6F10.1A6) and subsequently with streptavidin-APC. TCR 
Vβ usage was determined by flow cytometry using the Mouse Vβ 
TCR screening panel (BD Pharmingen). Intracellular cytokine 
staining was performed using the ICS kit from BioLegend accord-
ing to manufactures protocol. In short, cells were permeabilized 
for 20 min with the fixation buffer on ice, washed twice in wash-
ing buffer, and thereafter stained for IFNγ (XMG1.2, Biolegend). 
Cells were analyzed on a FACS Calibur or Fortessa (BD), and all 
analysis was performed using FlowJo software (Treestar).
In Vitro T cell stimulations
For in vitro recognition of T cells from the original T cell clone, 
5,000 T cells were co-cultured overnight with titrating amounts 
of tumor cells in 96-well U-bottom plates. For peptide stimula-
tion, 1 µg/ml peptide was added to the wells and at day 1 and 
day 2. These peptides were tested: Med15 (RLIIHFRDI), Qdm 
(AMAPRTLLL), FAP (FAPLPRLPTL), HSP60 (GMKFDRGYI), 
and FL9 (FYAEATPML). Splenocytes transduced with cloned 
TCR genes from Ln12 T  cell clone or control retrovirus were 
used as effector cells (100,000 per well) and stimulated with 
1  µg/ml peptide in 96-well U-bottom plates. Overnight IFNγ 
production by T cells was determined by ELISA. T cell stimula-
tion assays with freshly isolated transgenic Ln12.Rag1−/− T cells 
were performed with pooled spleen and lymph node cells. CD8+ 
T cells were purified using the CD8+ enrichment kit (BD) and 
labeled with 5  µM CFSE. A total of 100,000 cells were treated 
in a 96-well with various stimuli in the presence of 10 CU IL-2/
ml. For αCD3/αCD28 stimulation, wells were coated overnight 
with 0.5 µg/ml αCD3 (145-2C11, BD). The next day, coated wells 
were washed with medium and cells were added with 2  µg/ml 
αCD28 (37.51, Biolegend). Cells were analyzed by flow cytometry 
and supernatants were analyzed for cytokine release measured by 
IFNγ ELISA.
statistics
Statistical analyses were performed in GraphPad Prism, version 
7.0. P-values <0.05 were considered statistically significant and 
indicated with *, p < 0.01 with **, and p < 0.001 with ***.
resUlTs
conserved Tcr Vα Usage by Qa-1b-
restricted cD8+ T cells
Previously, we described the generation of Qa-1b-restricted 
T  cell responses specific for target cells that lack the peptide 
transporter TAP (27). We investigated the diversity of three 
of these independently isolated CD8+ TCRαβ+ T  cell clones 
(Ln12, Ln14, and Ln25) using a panel of TCR-Vβ-specific 
antibodies (Figure 1A). Each T cell clone expressed a different 
V-segment of the TCRβ chain: Vβ10 (ln12), Vβ4 (Ln14), and 
Vβ11 (Ln25), confirming their independent origin. Cloning 
and sequencing the TCRβ showed that the J- and D-segments 
as well as the CDR3 regions were also different (Figure  1B; 
Figure S1 in Supplementary Material). Interestingly, all three 
T cell clones expressed the same V-gene segment of the TCRα 
chains, namely TRAV13D-4 (Figure 1B). The J-segments and 
CDR3 regions of the TCRα chains, however, were different for 
each T cell. Thus, the TCR usage of these three Qa-1b-restricted 
T  cell clones was generally diverse, but conserved in the Vα 
segment. Interestingly, limited TCR Vα diversity was recently 
also described for Qa-1b-restricted T  lymphocytes specific for 
ERAAP-deficient target cells, although another Vα usage was 
reported for these CD8+ T cells (32).
FigUre 2 | Splenocytes and dendritic cells from TAP1−/− mice present non-mutated neoantigens. T cell clones were tested against titrated numbers of splenocytes 
(a) and dendritic cells (B) from wild-type B6 or TAP1−/− mice. The TLR4 ligand LPS was added to target cells to activate them. A twofold titration of target cells was 
tested, starting with 20,000 cells (splenocytes) or 10,000 cells (DC) per well. IFNγ release by T cells was determined as a measure of reactivity. Data are shown as 
mean with SD of triplicates from one out of two similar experiments. n.d., not determined.
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TaP-Deficiency induces Presentation of 
Peptide ligands in splenocytes and 
Dendritic cells
The absence of the peptide transporter TAP has an extensive 
impact on the surface levels of classical MHC class I molecules 
(33). We determined the consequence of TAP-deficiency for 
the nonclassical Qa-1b and examined surface display on freshly 
isolated splenocytes and in vitro cultured bone-marrow derived 
dendritic cells (Figure S2 in Supplementary Material). Although 
Qa-1b levels were indeed lower on TAP1−/− cells compared to wild 
type, the difference was very small. Activation of the splenocytes 
and dendritic cells by the TLR-4 ligand LPS even further decreased 
this difference. Presentation of the dominant Qdm peptide is 
known to be dependent on the peptide transporter (3, 34), thus 
the Qa-1b molecules on the surface of TAP1−/− cells have to be 
filled with an alternative TAP-independent peptide repertoire 
of ‘self ’ origin. We tested our three T  cell clones for reactivity 
against these non-transformed target cells. Even though these 
CD8+ T  cell clones had been generated against TAP-deficient 
tumor cells, they were able to recognize non-transformed sple-
nocytes and dendritic cells of TAP1−/− background (Figure  2). 
Short stimulation of TAP-deficient splenocytes with LPS resulted 
in strongly increased IFNγ release by the T  cells (Figure  2A). 
Comparable results were obtained with LPS pretreated dendritic 
cells (Figure 2B), indicating that activation of antigen-presenting 
cells leads to increased reactivity by Qa-1b-restricted CD8+ 
T cells. This effect might partially be explained by higher Qa-1b 
levels at the cell surface (Figure S2 in Supplementary Material). 
From these data, we concluded that all three independent T cell 
clones specifically recognized natural peptide ligands presented 
by non-transformed TAP-deficient target cells.
Qa-1b-Presented Peptide ligands are 
conserved across species
Next, we assessed the nature of the TAP-independent peptide 
ligands by transfection of the mouse Qa-1b gene H-2T23 into 
TAP-deficient human target cells (Figure 3). The mouse T cell 
clones were, therefore, tested against human T2 cells, which 
lost the chromosome locus coding for TAP1 and TAP2, and 
human HeLa cells rendered TAP-deficient through a TAP-
inhibition protein (BTIP) coded by the viral UL49.5 gene (35). 
Interestingly, all three T cell clones showed vigorous reactivity 
to Qa-1b-positive TAP-deficient human cells (Figures  3A,B). 
Parental T2 and HeLa cells were not recognized, nor HeLa cells 
expressing only Qa-1b. Interestingly, the absence of the peptide 
transporter was not required when higher levels of Qa-1b were 
introduced in HeLa cells (Figure 3C, Qa-1high). With five times 
higher surface Qa-1b (Figure S2B in Supplementary Material) 
also the TAP-proficient HeLa cells were recognized by the T cell 
clone (Figure  3C). We hypothesize that saturating availability 
of Qa-1b heavy chains consumed all Qdm peptides and thereby 
facilitate presentation of the alternative peptides. Finally, we 
found also T cell reactivity against COS-7 cells, which are kidney 
cells from an African green monkey (Figure 3D). Together, these 
data demonstrated the conserved nature of the T cell peptide-
epitopes presented by Qa-1b, even though exact sequences were 
not identified.
Qa-1b-restricted Tcr have an extended 
interface with Peptide residues
We aimed to identify the cognate peptide-epitopes of our T cell 
clones at the molecular level. None of the known Qa-1b-presented 
T cell epitopes were recognized by our T cells (Figure 4A). Thus, 
FigUre 4 | The Ln12 T cell peptide-epitope Med15 is immunogenic. The 
peptide derived from the Med15 cofactor for RNA polymerase II with 
sequence RLIIHFRDI is recognized by Ln12 T cells and immunogenic in C57/
BL6 mice. (a) Ln12 T cell clone was tested against the Med15 peptide and 
other previously reported Qa-1b-binding peptides. (B) Med15 or Qdm 
peptides were used for immunization of C57/BL6 mice. Five days after the 
booster immunization, blood samples were taken and frequencies of CD8+ 
T cell responses were measured by intracellular IFNγ staining after brief  
ex vivo stimulation with immunized peptide or medium. Shown are means 
and SEM from eight mice. (c,D) Immunized C57/BL6 mice were challenged 
with a mix of three different splenocyte populations that were peptide-loaded 
and differentially labeled with CFSE. Splenocytes were injected at day 5 after 
booster immunization and harvested at day 7. Specific in vivo killing of these 
labeled target cells was calculated using the unloaded splenocyte subset as 
reference. Compiled data (n = 9) of three independent experiments with 
similar results are shown as mean with SEM. Student’s t-test was used for 
statistical analyses.
FigUre 3 | Qa-1b-restricted CD8+ T cell recognize conserved peptides from 
human and monkey. T cell clones were tested against human T2 cells and 
HeLa cells and monkey COS-7 cells. (a) Human TAP-negative T2 lymphoma 
cells were transduced with the gene for Qa-1b. (B) Human HeLa cells were 
transduced with the Qa-1b gene and the viral TAP-inhibitor BTIP (=UL49.5). 
(c) TAP-proficient HeLa cells were selected for low or high surface 
expression of Qa-1b. (D) Monkey COS-7 cells were rendered Qa-1b positive 
by gene transfer. Twofold titration of target cells are depicted, starting with 
20,000 cells per well and T cell activation was measure via IFNγ production. 
Data are representative for at least two independent experiments with 
comparable results, shown as mean and SD of triplicates.
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a synthetic bead-assisted peptide library with a complexity of 
650,000 different 9-mer peptides was screened with the Ln12 
T cell clone. This screen yielded an agonistic mimotope peptide 
with sequence ILIYHFRGV. To map the promiscuity of the TCR 
for Qa-1b-bound peptide ligands, each position of this mimo-
tope sequence was exchanged for all other amino acids, and 
this collection of 171 synthetic peptides was tested in titrating 
concentrations for stimulation of the T  cell clone Ln12 (Table 
S1 in Supplementary Material). Most amino acid replacements 
completely abolished T  cell recognition, especially positions 2, 
3, and 5 were very critical and nearly all alternative amino acids 
turned the mimotope into non-stimulating ligands. Positions 1 
and 8 were indifferent for the TCR and nearly all other amino 
acids were allowed, or even improved, T cell reactivity. Position 
2 and 9 have been described as dominant anchor positions for 
binding to the groove of Qa-1b with preferred amino acids L and 
M (7, 36), suggesting that positions 3, 4, 5, 6, and 7 influenced the 
TCR interface. Thus, the Ln12 TCR is very peptide selective and 
does not merely engage Qa-1b heavy chains when stabilized by 
any Qa-1b-binding peptide.
TaBle 1 | T cell receptor specificity.
aa position
1 2 3 4 5 6 7 8 9
I L I Y H F R G Va
R L I I H F R D Ib
A L I F H C I A F
C V I I F K C I
D L Y M M D L
E V Q P E M
















aAll positions of the agonistic peptide ILIYHFRGV were replaced and tested with Ln12 
T cells (Table S1 in Supplementary Material), resulting in the indicated susceptible aa.
bAll natural peptides fulfilling this motif were tested with Ln12 (Table S2 in 
Supplementary Material), yielding the Med15 peptide (RLIIHFRDI).
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The conserved Med15-Derived Peptide is 
a ligand for ln12 T cells
The susceptible amino acids at each position that allowed 
activation of the Ln12 TCR, as depicted in Table 1, were used 
for a pattern homology search in the mouse proteome data-
base in order to select naturally occurring agonistic peptides. 
The search with this “TCR motif ” yielded 82 natural peptide 
sequences that were synthesized and tested in titrating concen-
trations for recognition by the Ln12 T cell clone (Table S2 in 
Supplementary Material). Out of these 82 naturally occurring 
peptides, only 6 stimulated the T cells at concentrations lower 
than 100  ng/ml and only one (RLIIHFRDI) was reactive as 
low as 100 pg/ml. This optimal peptide was derived from the 
Mediator complex subunit 15 (Med15), a cofactor involved in 
RNA polymerase II-dependent transcription. Interestingly, 
this peptide sequence was completely conserved in humans, 
underlining the finding that human cells were recognized upon 
Qa-1b expression by Ln12 T cells (Figure 3). Of note, although 
the Ln25 and Ln14 T  cell clones also recognized the human 
target cells, they did not react to the Med15 peptide, indicating 
that these two Qa-1b-restricted T cell clones recognize yet other 
peptide ligands.
strict central Tolerance for T cells to 
Qdm, but not to the Med15 ligand
Next, we determined if the identified Med15 peptide could 
also stimulate CD8+ T  cells from the natural repertoire via 
vaccination. Up to 7% of CD8+ T  cells responded to Med15 
after peptide vaccination, whereas the Qdm peptide failed to 
induce a T cell response (Figure 4B). This vaccination-induced 
T cell immunity was cytotoxic, as CFSE-labeled and peptide-
loaded splenocytes were efficiently and selectively killed 
in  vivo (Figures  4C,D). As controls, naïve mice did not kill 
Med15-loaded targets and Med15-immunized mice did not kill 
Qdm-loaded targets, indicating that bona fide cytotoxic CD8+ 
T cells were elicited by peptide vaccination. The fact that wild-
type mice are tolerant for Qdm-specific responses underlines 
its dominant presentation in homeostasis and strong clonal 
T cell deletion in the thymus. Together, these data imply that 1. 
the Ln12 TCR targets a specific peptide ligand and not merely 
stabilized Qa-1b molecules; 2. the degree of degeneracy of this 
TCR is comparable to that of conventional T cells; and 3. each 
Qa-1b-restricted T cell clone targets a different agonistic peptide. 
These characteristics are largely reminiscent of conventional 
hypervariable CD8+ T  cells, but not of invariant T  cells like 
NKT and MAIT.
Thymus selection of ln12 Tcr is Qa-1b-
independent
To study the thymus selection of Qa-1b-restricted Ln12 T cells, a 
TCR transgenic mouse was generated under control of the early 
CD2-based promoter. Transient expression of the cloned TCRαβ 
in splenocytes resulted in surface display and Med15-directed 
reactivity (Figures  5A,B), confirming correct cloning of the 
genes and demonstrating that the TCR confers the reactivity of 
Ln12 T  cells. TCR transgenic mice (hereafter called Ln12 tg) 
were crossed on a Rag1−/− background to prevent expression of 
endogenous TCRs and flow cytometry analysis was performed 
on the thymuses (Figures  5C,D). The frequency of immature 
CD4+CD8+ double positive thymocytes was increased in the 
Ln12 tg thymus, mostly due to absence of mature CD4 single 
positive T  cells, demonstrating that the CD4 molecule does 
not support selection of Qa-1b-restricted T cells. Although the 
frequency of mature CD8 single positive thymocytes was not 
increased in the TCR tg (Figure 5C), the Vβ10+ CD8+ T cells 
were significantly increased (Figure 5D), suggesting inefficient 
positive selection. Total T cell numbers in the spleen were indeed 
low even tough thymus cellularity was comparable to RAG1+/+ 
wild-type mice (Figures  5C–E). Apparently, a low number of 
CD4+CD8+ double positive thymocytes developed into mature 
CD8 single positive T cells that populate the secondary lymph 
organs.
Importantly, no differences were observed in the thymus 
of Ln12 tg mice when backcrossed to Qa-1b−/− mice (“Ln12 tg 
Qa-1b−/−”) (Figure  5C). Very similar percentages of immature 
CD4+CD8+ thymocytes and mature CD8+ T cells were detected 
(Figure 5D). In the spleen of these mice, clear and comparable 
populations of TCR-Vβ10+ CD8+ transgenic T cells were present 
in Qa-1b−/− and Qa-1b+/+ mice (Figure 5E). Total cell counts of 
Ln12 tg cells in thymus and spleen of these two strains were also 
the same (Figures 5D,E), demonstrating that thymus selection 
of Ln12 tg T cells is independent of Qa-1b. We hypothesize that 
Ln12 tg T cells are selected on classical MHC class I molecules 
presenting a highly diverse peptide repertoire in the thymus and 
FigUre 5 | Selection of Ln12 T cell receptor (TCR)-transgenic cells is 
independent of Qa-1b. Generation and thymus selection analysis of a 
TCR-transgenic mouse based on the Ln12 TCR. (a) Splenocytes were 
retrovirally transduced with cloned alpha and beta (Vβ10) chains of the 
Ln12 T cell clone. (B) Transduced splenocytes were stimulated with Med15 
peptide in vitro and IFNγ release by splenocytes was measured. Data 
representative of three independent experiments with comparable results 
and shown as mean with SD of triplicates. (c) Representative flow 
cytometry plots of thymus and spleen of C57/BL6, Ln12 tg WT and Ln12 tg 
Qa-1−/− mice. Ln12 tg were both backcrossed to RAG1−/−. (D,e) Cellularity 
of thymus and spleen and absolute counts of Vβ10+ CD8+ T cells in thymus 
and spleen are depicted. One-way ANOVA was used for statistical 
analyses.
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ln12 tg T cells largely egress the Thymus 
as naïve cells and Display effector 
Functions after activation
We examined the phenotype and function of the TCR transgenic 
Qa-1b-restricted T cells in more detail. Peripheral T cells in the 
Ln12 tg mice displayed normal frequencies of CD44, CD62L, 
CD25, and CD69, witnessing a naïve phenotype (Figures 6A,B). 
An increased population of CD122 and a small enhancement of 
Ly6C-positive cells indicated an antigen-experienced phenotype, 
but these small increases were minute compared to T cell subsets 
with “agonist selection,” like self-reactive regulatory T cells, NKT, 
and MAIT cells (37). In addition, Ln12 tg T cells did not exhibit 
an activated status, as the cells did not proliferate ex vivo in 
culture medium (Figures 6C,D). Addition of the Med15 peptide, 
but not control Qdm peptide induced activation of the cells, 
leading to proliferation and IFNγ production (Figures  6C,D). 
Activation of the T  cells in  vivo was demonstrated by transfer 
into naïve C57BL/6 or TAP1−/− mice (Figure  6E). Eight days 
after T cell transfer, the majority of the cells were not detected 
anymore in TAP1−/− mice, whereas no loss of T cells was observed 
in the C57BL/6 hosts. Disappearance in TAP1−/− mice was most 
likely the result of cognate antigen encounter in the absence of 
co-stimulation.
Finally, we investigated the potential of Ln12 tg T  cells to 
respond to peptide vaccination. TCR-transgenic cells were 
transferred in wild-type hosts, which were subsequently 
vaccinated twice with the Med15 peptide or Qdm peptide 
(Figure 6F). Transferred T cells underwent massive expansion, 
reaching frequencies of up to 90% of the total CD8+ T cell pool 
in recipient mice, accompanied by an activated CD62Llow pheno-
type (Figure 6F). In contrast, Qdm peptide vaccination did not 
activate the cells. In vivo activated Ln12 tg T cells also exhibited 
reactivity to TAP-deficient dendritic cells and not to their TAP-
proficient counterparts, similar to the parental Ln12 T cell clone 
(Figures 6G and 2B).
Overall, our results demonstrate that Qa-1b-restricted CD8+ 
T cells display characteristics of both conventional hypervariable 
T cells as well as invariant T cells and can be classified as semi-
invariant T  cells, with only conserved Vα usage, positioned 
between these two known T cell subsets.
DiscUssiOn
In this study, we describe characteristics of the Qa-1b-restricted 
CD8+ T cell subset that are reminiscent of T cell subtypes target-
ing other conserved MHC class Ib molecules, like CD1d, MR1, 
and H2-M3. For some features, however, the Qa-1b subset strik-
ingly differs from these invariant NKT cells and MAIT T cells and 
resembles conventional hypervariable CD8αβ+ TCRαβ+ T cells. 
We postulate that the Qa-1b T  cell subset is closest to conven-
tional CD8+ T cells of all other alternative MHC-Ib recognizing 
populations.
In three independent T cell clones, a single Vα segment was 
used in conjunction with diverse CDR3 sequences and completely 
different Vβ TCR chains. This variance is much higher than 
that found in NKT and MAIT cells where completely invariant 
not on Qa-1b, which is strongly monomorphic with its Qdm 
peptide. Positively selected T cells then subsequently target Qa-1b 
plus peptide in the periphery.
FigUre 6 | Normal behavior of peripheral T cell receptor (TCR)-transgenic Ln12 T cells. Mature peripheral T cells of the TCR-transgenic mouse were examined. 
(a,B) Expression of activation markers on CD8+ T cells in spleens of C57BL/6 or Ln12 tg mice was measured by flow cytometry. Combined data from at least eight 
animals are depicted, shown as mean with SEM of single markers. Student’s t-test was used for statistical analyses. (c,D) In vitro stimulation of purified CD8+ T cells 
from Ln12 tg mice with Med15 or Qdm peptide. Proliferation and IFNγ release were measured. Data are representative of at least two independent experiments. (e) 
Naïve CFSE-labeled CD8+ T cells from Ln12 tg mice were i.v. transferred into C57BL/6 or TAP1−/−. After 8 days, blood of recipient mice was analyzed for the 
frequency of Ln12 tg T cells. Data shown from one of the three experiments. Each line represents an individual mouse. (F,g) Ln12 tg CD8+ T cells were transferred 
to C57BL/6 mice and subsequently vaccinated with Med15 or Qdm peptide. Frequency and activation status was followed in blood of recipient mice with the use of 
a congenic marker. Data shown are mean with SEM of three mice and one of the two comparable experiments is shown. (g) Intracellular IFNγ detection in purified 
T cells was measured by flow cytometry upon brief ex vivo incubation with dendritic cells (DC) or peptides.
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TCRα chains are used, including specific Jα segments, also in 
combination with a limited set of Vβs (38, 39). These invariant 
receptors target very conserved and monomorphic antigens in 
categories as glycolipids and vitamin B metabolites (39, 40). As a 
result, these T cell subsets regularly display self-reactivity, similar 
to FoxP3+ natural Treg cells, yet, another dedicated T cell lineage 
with specialized function (37, 41). The Qa-1b T cell population 
we describe here are clearly distinct from these T cell subsets, as 
both TCRα and TCRβ chains harbor much more diversity and, 
additionally, a diverse set of peptide epitopes are recognized (see 
Figure 1). Recently, a very restricted usage of only TCRα chains 
was observed in a TCRβ-transgenic mouse with specificity for 
a Qa-1b-presented peptide was reported (32). Though the Vα 
element in that study was not the same as we found, together, 
these findings indicate that the monomorphic Qa-1b molecule, 
normally presenting the dominant Qdm peptide in homeostasis 
(4) imposes a strong limitation to the pool of functional TCRs that 
engage this MHC class Ib molecule during the selection process. 
Qdm-reactive T cells were indeed efficiently removed from the 
normal T cell repertoire, most likely due to central tolerance (see 
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Figure 4). Importantly, we showed that thymus selection of our 
Qa-1b T cell specificity was independent of the presence of Qa-1b 
(see Figure  5), indicating that these TCRs engage other MHC 
class I molecules for positive selection in the thymus and then 
“cross-react” to peptide/Qa-1b complexes in the periphery. Such 
cross-reactivity between classical and non-classical MHC mol-
ecules was reported before (42, 43) and underlines the similarities 
of their structures (7). Together, these results implicate limited 
availability of suitable TCRs and, therefore, low T cell precursor 
frequencies, to target each peptide-epitope presented by Qa-1b.
The mentioned T  cell subsets targeting other MHC class Ib 
molecules, like CD1d, MR1, and H2-M3, have been described 
to leave the thymus with an activated phenotype, expressing 
high levels of CD44, CD69, CD122, and Ly6C (37, 41, 44). It was 
postulated that these T populations are equipped with this acti-
vated phenotype and organ-homing capacities in order to quickly 
respond upon infections much like innate lymphoid cells that 
lack a TCR. This activated phenotype of recent thymic emigrants 
is related to a so-called “agonist selection” in the thymus, where 
strong TCR triggers results in an already antigen-experienced 
phenotype. Indeed, FoxP3+ natural Treg cells, NKT  cells, and 
CD8αα intraepithelial lymphocytes are T cell subsets with agonist 
selection (37). Interestingly, these subsets have been reported to 
undergo a unique selection process, in that, hematopoietic cells in 
the thymus are critical for TCR triggering and positive selection, 
in contrast to conventional CD8+ T cells where thymus epithelial 
cells are key (37, 44, 45). Analysis of our TCR-transgenic mouse 
also revealed a higher proportion of activated thymic emigrants, 
regarding expression of CD122 and Ly6C. However, classical 
markers of “agonist selection,” like CD44 and CD25, were not 
enhanced, and the overall phenotype was much less convincing 
compared to real invariant T cell subsets and closer resembled the 
pattern of conventional T cells. Our findings corroborate those 
reported for Qa-1b-restricted T cells targeting ERAAP-deficient 
targets (26, 32).
The last characteristic that is shared by most MHC class Ib 
T cell subsets is the monomorphic nature of their antigens (39, 40). 
Hence, this feature is directly related to their invariant TCR chains. 
The alternative peptide repertoire, however, of Qa-1b emerging 
at the surface of cells with defects in their antigen-processing 
machinery, like ERAAP or TAP deficiency, is extensively diverse. 
Peptidome analyses revealed more than 80 different sequences in 
Qa-1b and more than 500 in HLA-E, when Qdm is withhold from 
binding (27, 28). These findings are underscored by a recent study 
in rhesus macaques vaccinated with a CMV vector encoding 
SIV antigens. An unexpected large fraction of vaccine-induced 
CD8+ T  cells were directed to MHC-E presenting a variety of 
SIV peptides (13). Thus, the human HLA-E molecule might very 
well serve as a non-polymorphic antigen presentation platform, 
allowing display of a multitude of peptide antigens. Importantly, 
our results on scanning the TCR interface using a collection of 
171 sequences based on the mimotope agonist revealed a critical 
and broad interaction with the Qa-1b bound peptide (see Table 1; 
Tables S1 and S2 in Supplementary Material). Several amino acid 
residues of the peptide were critical for proper T cell activation. 
Of interest, the reported structure of a human TCR interacting 
with a Qdm-like peptide in HLA-E showed a regular diagonal 
docking of the receptor, very similar to that of conventional TCRs 
(24), suggesting that a broad interaction with several peptide side 
chains is definitively possible. Finally, our in vivo results with the 
TCR-transgenic T  cells closely mimic a T  cell differentiation 
program of conventional T  cells: they largely emerge from the 
thymus as naïve lymphocytes, require priming for activation, and 
undergo a typical clonal expansion and subsequent contraction 
phase, resulting in memory cells (see Figure 6). Together, these 
results predict that exploitation of the universal HLA-E antigen 
presentation platform for immunotherapy of viral disease or can-
cer is feasible and will recruit an alternative T cell subset, which is 
quite conventional in its behavior.
eThics sTaTeMenT
All animal experiments were controlled by the animal welfare 
committee (IvD) of the Leiden University Medical Center and 
approved by the national central committee of animal experi-
ments (CCD) under the permit number AVD116002015271.
aUThOr cOnTriBUTiOns
Conception and design of the work (ED and TH); acquisition of 
data (ED, MS, BQ, US, and CO); analysis and interpretation of the 
data (ED, SB, and TH); writing the paper (ED and TH).
acKnOWleDgMenTs
We are grateful for the technical support from people of the 
transgenesis mouse facility in the LUMC and Dr. Sjef Verbeek for 
the generation of the ln12 TCR-transgenic mouse.
FUnDing
Financial support was received from the Dutch Cancer Society 
(KWF 2010-4785) for ED and the Portuguese Foundation for 
Science and Technology (SFRH/BD/33539/2008) to CO.
sUPPleMenTarY MaTerial




1. Jensen PE, Sullivan BA, Reed-Loisel LM, Weber DA. Qa-1, a nonclassical class 
I histocompatibility molecule with roles in innate and adaptive immunity. 
Immunol Res (2004) 29:81–92. doi:10.1385/IR:29:1-3:081 
2. Rodgers JR, Cook RG. MHC class Ib molecules bridge innate and acquired 
immunity. Nat Rev Immunol (2005) 5:459–71. doi:10.1038/nri1635 
3. Aldrich CJ, DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. Identification 
of a Tap-dependent leader peptide recognized by alloreactive T cells specific for 
a class Ib antigen. Cell (1994) 79:649–58. doi:10.1016/0092-8674(94)90550-9 
10
Doorduijn et al. Qa-1b-Restricted CD8+ T Cell Subset
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 60
4. DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. Dominance of a 
single peptide bound to the class I(B) molecule, Qa-1b. J Immunol (1997) 
158:2183–91. 
5. Kurepa Z, Hasemann CA, Forman J. Qa-1b binds conserved class I leader pep-
tides derived from several mammalian species. J Exp Med (1998) 188:973–8. 
doi:10.1084/jem.188.5.973 
6. van Hall T, Oliveira CC, Joosten SA, Ottenhoff TH. The other Janus face of 
Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes Infect 
(2010) 12:910–8. doi:10.1016/j.micinf.2010.07.011 
7. Zeng L, Sullivan LC, Vivian JP, Walpole NG, Harpur CM, Rossjohn J, et al.  
A structural basis for antigen presentation by the MHC class Ib molecule, 
Qa-1b. J Immunol (2012) 188:302–10. doi:10.4049/jimmunol.1102379 
8. Davies A, Kalb S, Liang B, Aldrich CJ, Lemonnier FA, Jiang H, et al. A peptide 
from heat shock protein 60 is the dominant peptide bound to Qa-1 in the 
absence of the MHC class Ia leader sequence peptide Qdm. J Immunol (2003) 
170:5027–33. doi:10.4049/jimmunol.170.10.5027 
9. Chun T, Aldrich CJ, Baldeon ME, Kawczynski LV, Soloski MJ, Gaskins HR. 
Constitutive and regulated expression of the class IB molecule Qa-1 in pancreatic 
beta cells. Immunology (1998) 94:64–71. doi:10.1046/j.1365-2567.1998.00475.x 
10. Tompkins SM, Kraft JR, Dao CT, Soloski MJ, Jensen PE. Transporters asso-
ciated with antigen processing (TAP)-independent presentation of soluble 
insulin to alpha/beta T cells by the class Ib gene product, Qa-1(b). J Exp Med 
(1998) 188:961–71. doi:10.1084/jem.188.5.961 
11. Lo WF, Woods AS, DeCloux A, Cotter RJ, Metcalf ES, Soloski MJ. Molecular 
mimicry mediated by MHC class Ib molecules after infection with Gram-
negative pathogens. Nat Med (2000) 6:215–8. doi:10.1038/72329 
12. Wooden SL, Kalb SR, Cotter RJ, Soloski MJ. Cutting edge: HLA-E binds a 
peptide derived from the ATP-binding cassette transporter multidrug resis-
tance-associated protein 7 and inhibits NK  cell-mediated lysis. J Immunol 
(2005) 175:1383–7. doi:10.4049/jimmunol.175.3.1383 
13. Hansen SG, Wu HL, Burwitz BJ, Hughes CM, Hammond KB, Ventura AB, 
et  al. Broadly targeted CD8(+) T  cell responses restricted by major histo-
compatibility complex E. Science (2016) 351:714–20. doi:10.1126/science. 
aac9475 
14. Heinzel AS, Grotzke JE, Lines RA, Lewinsohn DA, McNabb AL, Streblow DN, 
et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ 
T cells. J Exp Med (2002) 196:1473–81. doi:10.1084/jem.20020609 
15. Nattermann J, Nischalke HD, Hofmeister V, Ahlenstiel G, Zimmermann H, 
Leifeld L, et al. The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes 
HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am 
J Pathol (2005) 166:443–53. doi:10.1016/S0002-9440(10)62267-5 
16. Salerno-Goncalves R, Fernandez-Vina M, Lewinsohn DM, Sztein MB. 
Identification of a human HLA-E-restricted CD8+ T cell subset in volunteers 
immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid 
vaccine. J Immunol (2004) 173:5852–62. doi:10.4049/jimmunol.173.9.5852 
17. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, et al. 
Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced 
by human cytomegalovirus gpUL40. Science (2000) 287:1031. doi:10.1126/
science.287.5455.1031 
18. Bian Y, Shang S, Siddiqui S, Zhao J, Joosten SA, Ottenhoff THM, et al. MHC Ib 
molecule Qa-1 presents Mycobacterium tuberculosis peptide antigens to CD8+ 
T cells and contributes to protection against infection. PLoS Pathog (2017) 
13:e1006384. doi:10.1371/journal.ppat.1006384 
19. Caccamo N, Pietra G, Sullivan LC, Brooks AG, Prezzemolo T, La Manna MP, 
et  al. Human CD8 T  lymphocytes recognize Mycobacterium tuberculosis 
antigens presented by HLA-E during active tuberculosis and express type 2 
cytokines. Eur J Immunol (2015) 45:1069–81. doi:10.1002/eji.201445193 
20. Joosten SA, van Meijgaarden KE, van Weeren PC, Kazi F, Geluk A, Savage ND, 
et al. Mycobacterium tuberculosis peptides presented by HLA-E molecules are 
targets for human CD8 T-cells with cytotoxic as well as regulatory activity. 
PLoS Pathog (2010) 6:e1000782. doi:10.1371/journal.ppat.1000782 
21. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H. Analysis of 
regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol (2004) 5:516–23. 
doi:10.1038/ni1063 
22. Jiang H, Canfield SM, Gallagher MP, Jiang HH, Jiang Y, Zheng Z, et al. HLA-E-
restricted regulatory CD8(+) T cells are involved in development and control 
of human autoimmune type 1 diabetes. J Clin Invest (2010) 120:3641–50. 
doi:10.1172/JCI43522 
23. Kim HJ, Verbinnen B, Tang X, Lu L, Cantor H. Inhibition of follicular T-helper 
cells by CD8(+) regulatory T cells is essential for self tolerance. Nature (2010) 
467:328–32. doi:10.1038/nature09370 
24. Hoare HL, Sullivan LC, Pietra G, Clements CS, Lee EJ, Ely LK, et al. Structural 
basis for a major histocompatibility complex class Ib-restricted T cell response. 
Nat Immunol (2006) 7:256–64. doi:10.1038/ni1312 
25. O’Callaghan CA, Tormo J, Willcox BE, Braud VM, Jakobsen BK, 
Stuart DI, et al. Structural features impose tight peptide binding specificity 
in the nonclassical MHC molecule HLA-E. Mol Cell (1998) 1:531–41. 
doi:10.1016/S1097-2765(00)80053-2 
26. Nagarajan NA, Gonzalez F, Shastri N. Nonclassical MHC class Ib-restricted 
cytotoxic T cells monitor antigen processing in the endoplasmic reticulum. 
Nat Immunol (2012) 13:579–86. doi:10.1038/ni.2282 
27. Oliveira CC, van Veelen PA, Querido B, de Ru A, Sluijter M, Laban S, et al. 
The nonpolymorphic MHC Qa-1b mediates CD8+ T  cell surveillance of 
antigen-processing defects. J Exp Med (2010) 207:207–21. doi:10.1084/
jem.20091429 
28. Lampen MH, Hassan C, Sluijter M, Geluk A, Dijkman K, Tjon JM, et  al. 
Alternative peptide repertoire of HLA-E reveals a binding motif that is 
strikingly similar to HLA-A2. Mol Immunol (2013) 53:126–31. doi:10.1016/j.
molimm.2012.07.009 
29. van Montfoort N, Camps MG, Khan S, Filippov DV, Weterings JJ, 
Griffith JM, et  al. Antigen storage compartments in mature dendritic cells 
facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl 
Acad Sci U S A (2009) 106:6730–5. doi:10.1073/pnas.0900969106 
30. Zhumabekov T, Corbella P, Tolaini M, Kioussis D. Improved version of a 
human CD2 minigene based vector for T cell-specific expression in transgenic 
mice. J Immunol Methods (1995) 185:133–40. doi:10.1016/0022-1759(95) 
00124-S 
31. Doorduijn EM, Sluijter M, Querido BJ, Oliveira CC, Achour A, Ossendorp F, 
et al. TAP-independent self-peptides enhance T cell recognition of immune-es-
caped tumors. J Clin Invest (2016) 126:784–94. doi:10.1172/JCI83671 
32. Guan J, Yang SJ, Gonzalez F, Yin Y, Shastri N. Antigen processing in the 
endoplasmic reticulum is monitored by semi-invariant alphabeta TCRs spe-
cific for a conserved peptide-Qa-1b MHC class Ib ligand. J Immunol (2017) 
198:2017–27. doi:10.4049/jimmunol.1600764 
33. Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant 
mice are deficient in antigen presentation, surface class I molecules, and 
CD4-8+ T  cells. Cell (1992) 71:1205–14. doi:10.1016/S0092-8674(05) 
80068-6 
34. van Hall T, Laban S, Koppers-Lalic D, Koch J, Precup C, Asmawidjaja P, et al. 
The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation 
of CTL epitopes by Qa-1b1. J Immunol (2007) 178:657–62. doi:10.4049/
jimmunol.178.2.657 
35. Koppers-Lalic D, Reits EA, Ressing ME, Lipinska AD, Abele R, Koch J, et al. 
Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of 
the transporter associated with antigen processing. Proc Natl Acad Sci U S A 
(2005) 102:5144–9. doi:10.1073/pnas.0501463102 
36. Kraft JR, Vance RE, Pohl J, Martin AM, Raulet DH, Jensen PE. Analysis of 
Qa-1(b) peptide binding specificity and the capacity of CD94/NKG2A to 
discriminate between Qa-1-peptide complexes. J Exp Med (2000) 192:613–24. 
doi:10.1084/jem.192.5.613 
37. Stritesky GL, Jameson SC, Hogquist KA. Selection of self-reactive T  cells 
in the thymus. Annu Rev Immunol (2012) 30:95–114. doi:10.1146/annurev- 
immunol-020711-075035 
38. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 
(2007) 25:297–336. doi:10.1146/annurev.immunol.25.022106.141711 
39. Birkinshaw RW, Kjer-Nielsen L, Eckle SB, McCluskey J, Rossjohn J. MAITs, 
MR1 and vitamin B metabolites. Curr Opin Immunol (2014) 26:7–13. 
doi:10.1016/j.coi.2013.09.007 
40. Kain L, Costanzo A, Webb B, Holt M, Bendelac A, Savage PB, et al. Endogenous 
ligands of natural killer T  cells are alpha-linked glycosylceramides. Mol 
Immunol (2015) 68:94–7. doi:10.1016/j.molimm.2015.06.009 
41. de Jong A, Pena-Cruz V, Cheng TY, Clark RA, Van Rhijn I, Moody DB. CD1a-
autoreactive T cells are a normal component of the human alphabeta T cell 
repertoire. Nat Immunol (2010) 11:1102–9. doi:10.1038/ni.1956 
42. Maurice MM, Gould DS, Carroll J, Vugmeyster Y, Ploegh HL. Positive 
selection of an MHC class-I restricted TCR in the absence of classical MHC 
11
Doorduijn et al. Qa-1b-Restricted CD8+ T Cell Subset
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 60
class I molecules. Proc Natl Acad Sci U S A (2001) 98:7437–42. doi:10.1073/
pnas.141143298 
43. Reed-Loisel LM, Sullivan BA, Laur O, Jensen PE. An MHC class Ib-restricted 
TCR that cross-reacts with an MHC class Ia molecule. J Immunol (2005) 
174:7746–52. doi:10.4049/jimmunol.174.12.7746 
44. Urdahl KB, Sun JC, Bevan MJ. Positive selection of MHC class Ib-restricted 
CD8+ T  cells on hematopoietic cells. Nat Immunol (2002) 3:772–9. 
doi:10.1038/ni814 
45. Engel I, Kronenberg M. Making memory at birth: understanding the dif-
ferentiation of natural killer T cells. Curr Opin Immunol (2012) 24:184–90. 
doi:10.1016/j.coi.2012.01.012 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Doorduijn, Sluijter, Querido, Seidel, Oliveira, van der Burg and 
van Hall. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in other 
forums is permitted, provided the original author(s) or licensor are credited and that 
the original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply with 
these terms.
